Fraunhofer-Gesellschaft

Publica

Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

AGMO Inhibitor Reduces 3T3-L1 Adipogenesis

 
: Fischer, C.; Wilken-Schmitz, A.; Hernandez-Olmos, V.; Proschak, E.; Stark, H.; Fleming, I.; Weigert, A.; Thurn, M.; Hofmann, M.; Werner, E.R.; Geisslinger, G.; Niederberger, E.; Watschinger, K.; Tegeder, I.

:
Volltext ()

Cells 10 (2021), Nr.5, Art. 1081, 20 S.
ISSN: 2073-4409
Englisch
Zeitschriftenaufsatz, Elektronische Publikation
Fraunhofer ITMP ()

Abstract
Alkylglycerol monooxygenase (AGMO) is a tetrahydrobiopterin (BH4)-dependent enzyme with major expression in the liver and white adipose tissue that cleaves alkyl ether glycerolipids. The present study describes the disclosure and biological characterization of a candidate compound (Cp6), which inhibits AGMO with an IC50 of 30–100 µM and 5–20-fold preference of AGMO relative to other BH4-dependent enzymes, i.e., phenylalanine-hydroxylase and nitric oxide synthase. The viability and metabolic activity of mouse 3T3-L1 fibroblasts, HepG2 human hepatocytes and mouse RAW264.7 macrophages were not affected up to 10-fold of the IC50. However, Cp6 reversibly inhibited the differentiation of 3T3-L1 cells towards adipocytes, in which AGMO expression was upregulated upon differentiation. Cp6 reduced the accumulation of lipid droplets in adipocytes upon differentiation and in HepG2 cells exposed to free fatty acids. Cp6 also inhibited IL-4-driven differentiation of RAW264.7 macrophages towards M2-like macrophages, which serve as adipocyte progenitors in adipose tissue. Collectively, the data suggest that pharmacologic AGMO inhibition may affect lipid storage.

: http://publica.fraunhofer.de/dokumente/N-636701.html